Collegium to Report Second Quarter 2026 Financial Results on August 6, 2026
Collegium Pharmaceutical (Nasdaq: COLL) announced it will report its second quarter 2026 financial results before the U.S. market opens on Thursday, August 6, 2026.
Rhea-AI Summary
Collegium Pharmaceutical (Nasdaq: COLL) announced it will report its second quarter 2026 financial results before the U.S. market opens on Thursday, August 6, 2026. Immediately afterward, the company will host a live conference call and webcast at 8:00 a.m. ET to discuss the results.
Investors can join the call by dialing (877) 407-8037 in the U.S. or (201) 689-8037 internationally and referencing the “Collegium Pharmaceutical Q2 2026 Earnings Call.” A live and replay webcast will be available in the Investors section of www.collegiumpharma.com, with replay access beginning approximately two hours after the event.
Positive
- None.
Negative
- None.
Details
News Market Reaction – COLL
In the Jul 23 session, COLL gained 2.51%, reflecting a moderate positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
- Reporting period
- Q2 2026
- Financial results to be reported
- Report date
- August 6, 2026
- Before the market opens
- Conference call time
- 8:00 a.m. ET
- Following the financial results release
- Replay availability
- Approximately two hours
- After the event
Previous Earnings date Reports
-
Scheduled first-quarter results before the market opened on May 7, 2026
-
Scheduled fourth-quarter and full-year results before the market opened
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
AI-generated analysis. How Rhea-AI works. Not financial advice.
STOUGHTON, Mass., July 23, 2026 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a leading biopharmaceutical company focused on improving the lives of people living with serious and often misunderstood conditions, today announced that it will report second quarter 2026 financial results before the market opens on Thursday August 6, 2026. Following the release of the financials, the Company will host a live conference call and webcast at 8:00 a.m. ET.
Conference Call Information
To access the conference call, please dial (877) 407-8037 (U.S.) or (201) 689-8037 (International) and reference the “Collegium Pharmaceutical Q2 2026 Earnings Call.” An audio webcast will be accessible from the Investors section of the Company’s website: www.collegiumpharma.com. The webcast will be available for replay on the Company’s website approximately two hours after the event.
About Collegium Pharmaceutical, Inc.
Collegium Pharmaceutical is a dynamic, biopharmaceutical company delivering medicines with formulation and delivery innovation for people living with complex central nervous system and pain conditions. Collegium has spent more than a decade proving that responsible stewardship and bold, science-backed approaches can redefine what treatment looks like in categories too often shaped by complexity and misconceptions.
With a portfolio of differentiated ADHD medications, anchored by JORNAY PM® (methylphenidate HCl) and AZSTARYS® (serdexmethylphenidate and dexmethylphenidate), and an established leadership position in responsible pain management, Collegium leads with the scientific rigor and commercial expertise to deliver treatment options around how people live their lives. For more information, please visit collegiumpharma.com or find us on LinkedIn.
Investor Contact:
Ian Karp
Head of Investor Relations
ir@collegiumpharma.com
Media Contact:
Jessica Cotrone
Senior Vice President, Communications & Corporate Affairs
communications@collegiumpharma.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.